Every 10-Q that Oramed Pharmaceuticals Inc. (ORMP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ORMP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORMP filings page.
Oramed Pharmaceuticals reported results for the six months ended June 30, 2026, after transforming into a strategic healthcare holding and operating company with no direct revenue-generating operations. Total assets rose to $369.6M from $230.9M, driven mainly by investment gains.
The company recorded a net income of $116.5M for the first half of 2026 and $78.2M for the quarter, largely from fair value increases in investments, especially its Alpha Tau stake and related warrants, which together were valued at about $211.3M. Core operations generated an operating loss of $6.4M, with R&D and G&A expenses totaling $6.4M.
Following the Lifeward transaction, Oramed transferred its POD oral insulin technology into OraTech, received Lifeward equity, warrants, convertible notes and a revenue-sharing right, and no longer conducts clinical development directly. Cash and cash equivalents declined to $15.2M, reflecting investment activity, a $0.25 per share special dividend (about $10.9M including equivalents), and tax withholdings on stock-based awards. The balance sheet now emphasizes concentrated financial investments, including Scilex notes subject to extension arrangements and high discount rates, and several real-estate–linked and private fund positions.
Oramed Pharmaceuticals reported net income of $38.3M for the three months ended March 31, 2026, compared with a net loss of $7.6M a year earlier. Basic EPS was $0.94.
Operating loss narrowed to $3.7M as research and development and general and administrative expenses declined. The swing to profitability was driven mainly by $44.8M of net financial income, including large fair value gains on investments such as Alpha Tau and Scilex, plus $8.3M of other income from a POD technology IP sale and recognizing $2.0M under the Medicox license.
Cash and cash equivalents fell to $13.2M from $45.9M at year-end 2025, while total assets increased to $268.8M as investment balances grew. The company completed the Lifeward transaction, transferring its POD technology into OraTech and receiving Lifeward shares, warrants and a convertible note, and it expanded its portfolio of structured investments and real estate–backed loans.
Oramed Pharmaceuticals (ORMP) reported a swing to profitability driven by investment revaluations. For the nine months ended September 30, 2025, net income attributable to stockholders was $54,041 thousand, including third‑quarter net income of $48,395 thousand. Financial income, net, reached $74,278 thousand, reflecting fair value gains primarily on Alpha Tau and Scilex exposures.
Total assets were $220,493 thousand with stockholders’ equity of $203,282 thousand. Cash and cash equivalents were $52,179 thousand. The company recognized $2,000 thousand of revenue tied to the HTIT License Agreement, while cost of revenue of $1,987 thousand related to IIA obligations.
Oramed expanded its investment portfolio: its Alpha Tau stake measured at fair value was $64,803 thousand, and it holds a 50% interest in RoyaltyVest. With Scilex, Oramed received $13,000 thousand from the repurchase of 3,130,000 Subsequent Penny Warrants and retains an option for $14,000 thousand on 3,370,000 additional warrants on or before December 31, 2025. The company also continued a buyback program, repurchasing $732 thousand of shares year‑to‑date.
Oramed Pharmaceuticals, Inc. reports condensed consolidated interim results and disclosures for the quarter ended June 30, 2025. The company operates in a single reportable segment focused on research and development of orally delivered pharmaceuticals and vaccines. The filing details multiple strategic investments and financing arrangements, including a $36,900 investment in Alpha Tau Medical (yielding an unrealized gain of $7,138 recognized in the six months ended June 30, 2025), equity method accounting for a 50% interest in RoyaltyVest, and various loans and real estate investments presented at fair value.
The company continues to hold structured receivables and convertible notes related to Scilex, including Tranche A and Tranche B Notes, and warrants (including 6,500,000 Subsequent Penny Warrants) with monetization restrictions; as of June 30, 2025 Scilex had repaid $69,200 of the Tranche A Note. The company entered an Option Agreement (July 22, 2025) under which Scilex may repurchase Subsequent Penny Warrants for a total of $27,000, and the agreement could extend the Tranche A Note maturity if completed. The company discloses deferred revenue recognition related to an HTIT license arrangement and describes cash flows, fair value measurements, share-based compensation grants (PSUs/RSUs), and a limited stock repurchase program under which 163,869 shares were repurchased for $371.